Here, we demonstrate that the metabolism of glyceryl trinitrate (GTN) to nitric oxide (NO) occurs not only in bovine aortic smooth muscle cells (SMCs) but also in endothelial cells (ECs) and that this biotrandormation is enhanced by pretreatment with Escherichia coli lipopolysaccharide (LPS). Two bioassay systems were used: inhibition of platelet aggregation and measurement of cGMP after stimulation by NO of guanylate cyclase in SMCs or ECs. In addition, NO produced from GTN by cells was measured as nitrite (NO-), one of its breakdown products. Indomethacin (10 IAM)-treated SMCs or ECs enhanced the platelet inhibitory activity of GTN. This effect was abrogated by coincubation with oxyhemoglobin (oxyHb; 10 pM), indicating release of NO from GTN. LPS (0.5 ug/ml; 18 h) enhanced at least 2-to 3-fold the capacity of SMCs or ECs to form NO from GTN, and this enhancement was attenuated when cydoheximide (10 pug/ml) was incubated together with LPS. Furthermore, when incubated with GTN (200 pM) SMCs or ECs treated with LPS (0.5 pig/ml; 18 h) released more NO from GTN than nontreated cells as indicated by a much higher (8-to 9-fold) increase in the levels of cGMP. Exposure of SMCs to GTN (600 pAM) for 30 min led to an increase in the levels of NO-dependent on cell numbers, which was enhanced when SMCs were treated with LPS. Incubation of nontreated or LPS-treated cells with NGmonomethyl-L-arginine (300 pM; 60 min) did not influence the metabolism of GTN to NO. SMCs failed to enhance the antiplatelet activity of sodium nitroprusside. Anesthetized rats treated with an intraperitoneal injection of LPS (20 mg/kg) 18 h beforehand showed enhanced hypotensive responses to GTN (0.25-1 mg/kg). These effects were blocked by methylene blue (10 mg/kg) but not by indomethacin (3 mg/kg). LPS did not alter the hypotensive responses induced by phentolamine, verapamil, or SIN-1. Thus, both in vitro and in vivo, LPS induces the enzyme(s) metabolizing GTN to NO.
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The vasodilator effect of glyceryl trinitrate (GTN) and other organic nitrates such as isosorbide dinitrate is mediated through bioconversion to nitric oxide (NO) (1, 2) . NO stimulates the soluble guanylate cyclase by interacting with the ferroheme center of the enzyme, resulting in generation of cGMP (1) . Besides its vasodilator effect, GTN also inhibits platelet aggregation, although the concentrations required to do this in vitro are much greater than those required in vivo. Thus, platelets must have low levels of the enzymes or cofactors required to convert GTN to NO. However, in vitro the antiplatelet effectiveness of GTN can be enhanced in the presence of cells that metabolize GTN to NO, such as those in human arterial smooth muscle (3) .
The vasorelaxant and antiplatelet effects of NO are abolished by methylene blue, an inhibitor of the soluble guanylate cyclase (1, 4) and by oxyhemoglobin (oxyHb), which oxidizes NO into nitrates (5) . The pathways for the formation of NO from GTN are not yet defined. In fibroblasts and cultured smooth muscle cells (SMCs), NO formation is mediated by an enzymic mechanism (6, 7) and at least in bovine coronary smooth muscle cells the enzyme responsible for the metabolic activation of GTN to NO is associated with the plasma membrane (7) .
NO is also produced endogenously from L-arginine in various cells, including endothelial cells (ECs) (8) and SMCs (9, 10) . In these cell types, the release of NO can be enhanced by Escherichia coli lipopolysaccharide (LPS) (10, 11) . Interestingly, in pulmonary epithelial cells LPS can induce the expression of enzymes, such as glutathione-S-transferase (12) , thought to be involved in the bioconversion of GTN to NO in SMCs (13) . There is some evidence that the effects of NO derived tom GTN (14) may be inhibited by endogenous NO, although the mechanism for this is unclear.
We (17, 18) . SMCs were characterized by the presence of specific a-actin by using a 983 Sigma kit. Indomethacin (10 AuM) was always added to all final cell suspensions. In some experiments, LPS (0.5-10 pug/ml; serotype 0127:B8) was added to the SMCs or ECs in culture for 18 h before use. Cell viability in the absence or presence of LPS was >95%, as assessed by the uptake of trypan blue. Incubation of the cells with NG-monomethyl-Larginine (MeArg; Ultrafine Chemicals, Manchester, U.K.) for 60 min did not alter cell viability.
Platelet Aggregation. A suspension of human washed platelets (16) treated with indomethacin (10 lM) was incubated at 370C for 4 min in a Payton dual channel aggregometer (19) with continuous stirring at 1000 rpm and then stimulated with thrombin (40 milliunits/ml) to give a submaximal aggregation (80-90%). The decrease in optical density was recorded for 5 min. After a 3-min incubation with platelets, the inhibitory effects of GTN or sodium nitroprusside (NaNp) on platelet aggregation induced by thrombin were measured either alone or in the presence of SMCs or ECs not treated or treated with LPS (0.5 Ag/ml for 18 h). When required, oxyHb (10 AM) was added to the platelet mixture for the 3-min incubation. When using cells or oxyHb, the calibrations were performed in the presence of these agents to compensate for possible changes in light transmission (16) . Inhibition of platelet aggregation was calculated as described (16) .
Measurement of Cyclic Nucleotides. cGMP levels were measured by radioimmunoassay (20) after acetylation of the samples with acetic anhydride (21) . A suspension (105 cells) of either SMCs or ECs treated with LPS (0.5 ,ug/ml; 18 h) or nontreated was diluted in Krebs' buffer and incubated in an aggregometer for 3 min (37°C; 1000 rpm). Isobutylmethylxanthine (0.1 mM) was present in the incubation mixture to inhibit phosphodiesterase activity. GTN (200 ,uM) was added to the untreated or LPS-treated cells for 3 min. When required, oxyHb (10 ,AM) was added to cells alone or in the presence of GTN for 3 min. Ice-cold trichloroacetic acid [final concentration, 5% (wt/vol)] was then added, the samples were stored at -20°C, and the cyclic nucleotides were extracted from trichloroacetic acid with 0.5 M tri-noctylamine dissolved in 1,1,2-trichlorotrifluoroethane. All determinations were performed in duplicate.
Nitrite Analysis. Nitrite (NO-) in cell culture medium and that released by GTN in the presence or absence of untreated SMCs or SMCs treated with LPS (10 pgg/ml for 18 h) was measured by using the Griess reaction. A higher concentration of LPS (10 ,ug/ml) was required than in the experiments with platelet aggregation or guanylate cyclase assay, for the Griess reaction was much less sensitive than the bioassays. GTN (600 ,uM), untreated SMCs, or SMCs (1.5-6 x 106) treated with LPS or a mixture of GTN together with cells were diluted in Krebs' buffer containing indomethacin (10 ,uM) and superoxide dismutase (100 units/ml) and then exposed to stirring (37°C; 1000 rpm) for 30 min. The samples were centrifuged and each supernatant was allowed to react with the Griess reagent (1% sulfanilamide/0.1% naphthylethylenediamine dihydrochloride/2.5% H3PO4) to form a chromophore absorbing at 546 nm. Results were expressed as net amounts of NOj per ml by the following equation:
net amounts of NOI per ml = A -(B + C), where A is nmol of NOI per ml formed by GTN in the presence of cells; B is nmol of NO-per ml formed by GTN alone, and C is nmol of NO-per ml formed by cells alone.
In Vivo Measurements. Adult male Wistar Morini (S. Polo D'Enza, Reggio Emilia, Italy) normotensive rats (-250 g) were used throughout. The animals were anesthetized with sodium pentobarbital (55 mg/kg) before surgical preparation. Catheters (PE50), filled with heparinized saline (200 units/ ml), were inserted into the left common carotid artery to record blood pressure and heart rate. The jugular vein was cannulated for i.v. injections of drugs. The animals were allowed to stabilize at least 20 min after surgery. Blood pressure and heart rate were monitored on a Gemini polygraph via Bently transducers (Ugo Basile, Comerio Varese, Italy). The mean arterial pressure was calculated as the diastolic blood pressure plus one-third of the pulse pressure. To quantify drug-induced cardiovascular responses, the area under the curve of mean arterial pressure (expressed as mmHg/min) was calculated according to the trapezoidal rule (22) . GTN (0.25-1 mg/kg), phentolamine (0.25-1 mg/kg), verapamil (1-4 mg/kg), or SIN-1 (0.25 mg/kg) were given as infusions at 200 ,.l/min. Each rat was used for only one dose of the drug. Similar protocols were used in animals that had been pretreated with LPS (20 mg/kg dissolved in 0.5 ml of saline and injected i.p.) 18 h before surgery. In other experiments, rats were pretreated either with indomethacin (3 mg/kg) or with methylene blue (10 mg/kg) 30 min before GTN (0.25-1 mg/kg) administration.
Statistics. Results are expressed as means ± SEM for n experiments and each experiment was performed with blood obtained from a different donor. Student's unpaired t test was used to determine the significant difference between means, and a P value of <0.05 was taken as significant.
RESULTS

Potentiation of the Antiplatelet Activity of GTN by SMCs or
ECs and the Effects of LPS. In human washed platelets, GTN (22-352 gM) inhibited aggregation ( Fig. 1) , an effect that was prevented by oxyHb (n = 4; data not shown). The concentration of GTN required to inhibit platelet aggregation by 50% (IC50) was 110 + 2 p.M. However, the antiplatelet activities for GTN were profoundly magnified by small numbers of SMCs or ECs ( Fig. 1) Pharmacology: Salvemini et al. to 8% ± 1% inhibition; n = 4; P < 0.001 for SMCs and from 63% ± 5% inhibition to 2% ± 1% inhibition; n = 4; P < 0.001 for ECs). Similarly, potentiation of the antiplatelet activity of GTN by LPS-treated SMCs or ECs was attenuated by oxyHb (n = 4; data not shown). NaNp (4-64 ,M) inhibited platelet aggregation and this was abolished by oxyHb (23) . NaNp was 10 times more potent than GTN with an IC50 of 15 ± 1 ,M (n = 4). Thus, SMCs and to some extent ECs increase the antiplatelet potency of GTN to approach that of NaNp. The antiplatelet effects of NaNp were, in contrast, not changed by the presence of cells. For instance, NaNp (4 ,M) caused an approximately similar degree of inhibition (11% ± 6%; n = 4) to that obtained with GTN (44 ,M; 9% ± 1%; n = 16) but the addition of nontreated SMCs (0.24 x 105 cells; 6% ± 2% inhibition; n = 4) or LPS-treated SMCs (0.12 x 105 cells; 13% ± 1% inhibition; n = 4) did not enhance its inhibitory activity (19% ± 2% inhibition for NaNp together with nontreated cells and 28% ± 1% inhibition by NaNp together with LPS-treated cells).
Effects of MeArg. When SMCs (1.92 x 105) or ECs (3.2 x 105) were pretreated with MeArg (300 ,M; 60 min), their endogenous platelet inhibitory activity was attenuated (from 100% inhibition to 21% ± 2% inhibition and from 95% ± 3% inhibition to 15% ± 2% inhibition; n = 4; P < 0.0005). SMCs or ECs treated with MeArg did not, however, lose their ability to potentiate the antiplatelet action of GTN (from 21% ± 2% inhibition to 75% ± 2% inhibition and from 15% ± 2% inhibition to 60% + 3% inhibition in the absence or presence of GTN; n = 4; P < 0.005). Similarly, when the increased (from 97% ± 3% inhibition to 18% ± 1% inhibition and from 90% ± 6% inhibition to 11% ± 3% inhibition; n = 4; P < 0.005), their ability to enhance the antiplatelet activity of GTN was unchanged (from 18% ± 3% inhibition to 95% ± 3% inhibition and from 11% ± 3% inhibition to 80% ± 3% inhibition in the absence or presence of GTN; n = 4; P < 0.005).
Effects of Cycloheximide. Nitrite Production. Incubation of SMCs in culture for 18 h with LPS (10 ,ug/ml) increased the levels ofNOj in the media (from 0.25 ± 0.04 to 8.7 ± 1.5 nmol of NO-per ml; n = 12; P <0.001). The levels of NOj increased by LPS were due to stimulation of the L-Arg-NO pathway for MeArg (300 ,uM); when coincubated with LPS for 18 h this increase was abolished (from 8.7 ± 1.5 to 1 ± 0.5 nmol of NO-per ml; n = 12; P < 0.001). Exposure of SMCs (3 x 106) to GTN (600 tLM) for 15, 30, or 60 min led to a time-dependent production of NO-, which was maximal at 30 min (n = 4; data not shown). A period of 30 min was selected for the next experiments. Fig. 3 shows that exposure of SMCs in the absence or presence of LPS to GTN for 30 min led to a marked cell-dependent increase in NOj formation. This increase was greater in LPS-treated SMCs. Boiling the cells for 15 min abrogated the formation of NO-. Incubation of GTN for 30 min with bovine serum albumin (2 mg/ml) did not modify the formation of NO-from GTN (n = 3; data not shown).
Hemodynamic Responses to GTN in Nontreated or in LPSTreated Rats. GTN (0.25-1 mg/kg) caused a dose-dependent decrease in blood pressure (Fig. 4A ) and an increase in heart rate; these responses were abrogated by methylene blue (10 mg/kg i.v.; 30 min before GTN) (n = 4 for each dose; data not shown). The magnitude and duration of the hypotensive effects of GTN were enhanced when the animals had been pretreated for 18 h with LPS (20 mg/kg i.p.) (Fig. 4A ). Interestingly, LPS had a more striking potentiating action on the duration rather than peak fall in mean arterial pressure. Thus, after LPS pretreatment, the fall in peak mean arterial pressure by GTN at 0.25, 0.5, or 1 mg/kg was potentiated by 2-, 2-, and 1-fold, whereas the duration of the hypotensive effect was potentiated by at least 3-fold for each GTN concentration. This dose of LPS did not cause significant changes in blood pressure (in nontreated rats, 107 ± 3 mmHg; in LPS-treated rats, 97 ± 4 mmHg; n = 12). The potentiating
effects of LPS treatment on GTN administration were not affected by indomethacin (3 mg/kg i.v.; 30 min before GTN) but were blocked by methylene blue (10 mg/kg i.v.; 30 min before GTN) (Fig. 4B) . The hypotensive effects of verapamil (2 mg/kg), phentolamine (0.5 mg/kg), or SIN-1 (0.25 mg/kg) at concentrations that caused a similar decrease in blood pressure as that obtained with GTN at 1 mg/kg were not modified by the LPS treatment (n = 4; data not shown).
DISCUSSION
GTN dilates blood vessels and is converted to nitrites in the presence of vascular tissues (24) . NO is the active intermediate in the metabolism of organic nitrates (25) and its biological activity is destroyed by oxyHb which oxidizes NO to nitrate (5) . In this paper, we show that not only SMCs but also ECs metabolize GTN to NO and that LPS pretreatment induces an enzyme that enhances the metabolism of GTN to NO in both ECs and SMCs. SMCs or ECs potentiated the antiplatelet effects of GTN in an oxyHb-reversible manner. Since oxyHb cannot penetrate platelets (26) , the reversing effect observed with oxyHb must have been due to removal of NO from the extracellular medium. As NO is a potent inhibitor of platelet aggregation (27) , the potentiation of the antiplatelet activity of GTN by SMCs or ECs must be due to metabolism by the added cells of GTN to NO.
The antiplatelet effects of GTN in vivo are seen at concentrations of GTN much lower than those necessary to inhibit platelet aggregation in vitro. Cell number x 10-6 SMCs with or without LPS treatment failed to alter the antiplatelet activity of NaNp fits in with this conclusion.
Endogenous NO can, through stimulation of cGMP formation, exercise both autocrine and paracrine effects (32, 33) . Inhibition of basal NO formation by EC leads to the development of a supersensitivity of vascular smooth muscle to GTN and other vasodilators (14) . This effect may occur at the level of the soluble GC system in the smooth muscle (14) rather than on a modulatory action of NO on NO synthase, since NO does not affect the activity of this enzyme (34) . In the present study, we have shown that MeArg, an inhibitor of the L-Arg-NO pathway (35) 
